Amicus Therapeutics – A Biopharmaceutical Firm Based in New Jersey

Amicus Therapeutics is a biopharmaceutical firm based in New Jersey, America. The firm went public in 2007 under the trading name, NASDAQ (Google Finance). The establishment of Amicus Therapeutics was financed by selected capital venture firms such as Radius Venture, New Enterprise Associates, and Canaan Partners. The organization focuses on the treatment of rare and orphan diseases, more so lysosomal storage disorders. The product development of the company is primarily based on CHART (Chaperone-Advanced Replacement Therapy), as well as enzyme replacement therapies.
In 2014, Amicus Therapeutics was noted as one of the companies that have the broadest portfolio of pharmacological chaperones small molecule in the pharmaceutical industry. Moreover, Amicus Therapeutics has a robust development pipeline for the treatment of various human genetic disease. For example, Amicus Therapeutics has a lead product known as migalastat. The product is a personalized medicine that is used for treating people with Fabry disease. Amicus Therapeutics is also working in collaboration with JCR Pharmaceutical and GlaxoSmithKline to explore coformulation with the recombinant alpha-galactosidase. However, the collaboration lasted for only three years.
Amicus does not have the manufacturing capability to produce its products. It relies on contracts from other companies for the manufacturing process. However, in 2008, the company expanded its operation. Apart from the normal research site in New Jersey, Amicus Therapeutics also has another research site in San Diego. Since its establishment, Amicus has been on the good side of the business. In 2010, Amicus Therapeutics received a grant worth $500000 from Michael Joseph Fox Foundation. The grant was meant to support the research study that was being conducted by Amicus in partnership with David Geffen Medical School. The company also received another grant worth $210300 from ADDF (Alzheimer’s Drug Discovery Foundation). Amicus Therapeutics used the grant to support its pre-clinical work. Also, in 2013, Amicus was able to have the necessary intellectual property and proprietary materials for the treatment of Pompe infection.

For more information visit: https://www.crunchbase.com/organization/amicus-therapeutics

| Twitter

 

A Close Look at Clay Siegall’s Life.

Different scenarios inspire people to start up their businesses. Clay Siegall who is the chief executive officer and the founder of Seattle Genetic was inspired to initiate the company by his undying interest in medicine. He was always intrigued by the power of technology and always had the burden of overcoming diseases and restoring health to the sick. His interest in cancer treatment beckoned while he was a student of zoology at the University of Maryland. One of his family members fell ill. The treatment that he was under was quite brutal since the patient developed anemia as a result of chemotherapy. The situation became an eye opener. Clay Siegall realized there are other ways of treating cancer which are better. That is how his journey began.

 

Clay Siegall established Seattle Genetic in the year 1998. For the nearly two decades the company has existed, Dr. Siegall has brought it to the top of the targeted therapy industry. Seattle Genetic has developed its first ever FDA-approved antibody-drug conjugate which at present has many approved indications. It has also developed a robust pipeline of over 20 drugs. The firm prides itself in having a range of strategic partnerships with drug manufacturers such as Bayer, Pfizer, and Genentech among others.

Clay Siegall firmly believes that the old-guard of cancer treatment such as systemic chemotherapy is close enough to be forgotten. The reason is that as time flies, the efficacy and value of therapies on target become clearer. He also is of the sentiments that the old treatments will be overridden by the tolerable and much more efficient targeted drugs.

 

Before he came up with Seattle Genetics, Clay Siegall worked at the Bristol-Myers Squibb Pharmaceutical Research Institute for six years. From 1988 to 1991, he was working at the National Cancer Institute that is under the National Institute of Health. Clay Siegall serves as a member of the board at the Ultragenyx Pharmaceutical as well as Washington Roundtable.

 

Dr. Siegall has received awards such as the 2013 University of Maryland Alumnus of the Year for Computer and the coveted Pacific Northwest Ernst $ Young Entrepreneur of the year 2012.